Authors:
CONNE P
GAUTHEY L
VERNET P
ALTHAUS B
QUE JU
FINKEL B
GLUCK R
CRYZ SJ
Citation: P. Conne et al., IMMUNOGENICITY OF TRIVALENT SUBUNIT VERSUS VIROSOME-FORMULATED INFLUENZA VACCINES IN GERIATRIC-PATIENTS, Vaccine, 15(15), 1997, pp. 1675-1679
Authors:
KOLLARITSCH H
QUE JU
KUNZ C
WIEDERMANN G
HERZOG C
CRYZ SJ
Citation: H. Kollaritsch et al., SAFETY AND IMMUNOGENICITY OF LIVE ORAL CHOLERA AND TYPHOID VACCINES ADMINISTERED ALONE OR IN COMBINATION WITH ANTIMALARIAL-DRUGS, ORAL POLIO VACCINE, OR YELLOW-FEVER VACCINE, The Journal of infectious diseases, 175(4), 1997, pp. 871-875
Authors:
SHERWOOD JA
COPELAND RS
TAYLOR KA
ABOK K
OLOO AJ
WERE JBO
STRICKLAND GT
GORDON DM
BALLOU WR
BALES JD
WIRTZ RA
WITTES J
GROSS M
QUE JU
CRYZ SJ
OSTER CN
ROBERTS CR
SADOFF JC
Citation: Ja. Sherwood et al., PLASMODIUM-FALCIPARUM CIRCUMSPOROZOITE VACCINE IMMUNOGENICITY AND EFFICACY TRIAL WITH NATURAL CHALLENGE QUANTITATION IN AN AREA OF ENDEMIC HUMAN MALARIA OF KENYA, Vaccine, 14(8), 1996, pp. 817-827
Citation: Sj. Cryz et al., A VIROSOME VACCINE ANTIGEN DELIVERY SYSTEM DOES NOT STIMULATE AN ANTIPHOSPHOLIPID ANTIBODY-RESPONSE IN HUMANS, Vaccine, 14(14), 1996, pp. 1381-1383
Authors:
KOLLARITSCH H
FURER E
HERZOG C
WIEDERMANN G
QUE JU
CRYZ SJ
Citation: H. Kollaritsch et al., RANDOMIZED, DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF COMBINED SALMONELLA-TYPHI TY21A AND VIBRIO-CHOLERAE-CVD 103-HGR LIVE ORAL VACCINES, Infection and immunity, 64(4), 1996, pp. 1454-1457
Authors:
RUBINSTEIN A
GOLDSTEIN H
PETTOELLOMANTOVANI M
MIZRACHI Y
BLOOM BR
FURER E
ALTHAUS B
QUE JU
HASLER T
CRYZ SJ
Citation: A. Rubinstein et al., SAFETY AND IMMUNOGENICITY OF A V3 LOOP SYNTHETIC PEPTIDE CONJUGATED TO PURIFIED PROTEIN DERIVATIVE IN HIV-SERONEGATIVE VOLUNTEERS, AIDS, 9(3), 1995, pp. 243-251
Authors:
LANG AB
SCHAAD UB
RUDEBERG A
WEDGEWOOD J
QUE JU
FURER E
CRYZ S
Citation: Ab. Lang et al., EFFECT OF HIGH-AFFINITY ANTIPSEUDOMONAS AERUGINOSA LIPOPOLYSACCHARIDEANTIBODIES INDUCED IMMUNIZATION ON THE RATE OF PSEUDOMONAS-AERUGINOSAINFECTION IN PATIENTS WITH CYSTIC-FIBROSIS, The Journal of pediatrics, 127(5), 1995, pp. 711-717
Authors:
CRYZ SJ
QUE JU
LEVINE MM
WIEDERMANN G
KOLLARITSCH H
Citation: Sj. Cryz et al., SAFETY AND IMMUNOGENICITY OF A LIVE ORAL BIVALENT TYPHOID-FEVER (SALMONELLA-TYPHI TY21A) CHOLERA (VIBRIO-CHOLERAE CVD 103-HGR) VACCINE IN HEALTHY-ADULTS, Infection and immunity, 63(4), 1995, pp. 1336-1339
Authors:
BROWN AE
SINGHARAJ P
WEBSTER HK
PIPITHKUL J
GORDON DM
BOSLEGO JW
KRINCHAI K
SUARCHAWARATANA P
WONGSRICHANALAI C
BALLOU WR
PERMPANICH B
KAIN KC
HOLLINGDALE MR
WITTES J
QUE JU
GROSS M
CRYZ SJ
SADOFF JC
Citation: Ae. Brown et al., SAFETY, IMMUNOGENICITY AND LIMITED EFFICACY STUDY OF A RECOMBINANT PLASMODIUM-FALCIPARUM CIRCUMSPOROZOITE VACCINE IN THAI SOLDIERS, Vaccine, 12(2), 1994, pp. 102-108
Authors:
EDELMAN R
TAYLOR DN
WASSERMAN SS
MCCLAIN JB
CROSS AS
SADOFF JC
QUE JU
CRYZ SJ
Citation: R. Edelman et al., PHASE-1 TRIAL OF A 24-VALENT KLEBSIELLA CAPSULAR POLYSACCHARIDE VACCINE AND AN 8-VALENT PSEUDOMONAS O-POLYSACCHARIDE CONJUGATE VACCINE ADMINISTERED SIMULTANEOUSLY, Vaccine, 12(14), 1994, pp. 1288-1294
Authors:
CRYZ SJ
WEDGWOOD J
LANG AB
RUEDEBERG A
QUE JU
FURER E
SCHAAD UB
Citation: Sj. Cryz et al., IMMUNIZATION OF NONCOLONIZED CYSTIC-FIBROSIS PATIENTS AGAINST PSEUDOMONAS-AERUGINOSA, The Journal of infectious diseases, 169(5), 1994, pp. 1159-1162